[Management of atrial fibrillation comorbid with coronary heart disease].

Research output: Contribution to journalArticle

Abstract

Atrial fibrillation (AF) and coronary artery disease (CAD) can be comorbid with each other, because they can develop based on common risk factors such as aging, hypertension, diabetes mellitus and obesity. The management for stroke prevention in patients with AF and CAD needs some cautions. The vascular disease including CAD has been approved as one of the risk developing stroke in the CHA2DS2-VASc score for patients with AF. Patients with AF and CAD often should take antiplatelet and anticoagulant and sometimes take double antiplatelets and anticoagulant, which associates with increased bleeding risk. On terms of the management of AF, the medications of the rhythm control therapy for the AF would be limited if a patient has CAD. A K channel blocker would be selected for the 1st line therapy.

Original languageEnglish
Pages (from-to)142-147
Number of pages6
JournalNihon rinsho. Japanese journal of clinical medicine
Volume71
Issue number1
Publication statusPublished - 2013 Jan

Fingerprint

Atrial Fibrillation
Coronary Disease
Coronary Artery Disease
Anticoagulants
Stroke
Vascular Diseases
Diabetes Mellitus
Obesity
Hemorrhage
Hypertension
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

[Management of atrial fibrillation comorbid with coronary heart disease]. / Takatsuki, Seiji.

In: Nihon rinsho. Japanese journal of clinical medicine, Vol. 71, No. 1, 01.2013, p. 142-147.

Research output: Contribution to journalArticle

@article{e06a7537587e48fe8cd0b401808bc1ae,
title = "[Management of atrial fibrillation comorbid with coronary heart disease].",
abstract = "Atrial fibrillation (AF) and coronary artery disease (CAD) can be comorbid with each other, because they can develop based on common risk factors such as aging, hypertension, diabetes mellitus and obesity. The management for stroke prevention in patients with AF and CAD needs some cautions. The vascular disease including CAD has been approved as one of the risk developing stroke in the CHA2DS2-VASc score for patients with AF. Patients with AF and CAD often should take antiplatelet and anticoagulant and sometimes take double antiplatelets and anticoagulant, which associates with increased bleeding risk. On terms of the management of AF, the medications of the rhythm control therapy for the AF would be limited if a patient has CAD. A K channel blocker would be selected for the 1st line therapy.",
author = "Seiji Takatsuki",
year = "2013",
month = "1",
language = "English",
volume = "71",
pages = "142--147",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "1",

}

TY - JOUR

T1 - [Management of atrial fibrillation comorbid with coronary heart disease].

AU - Takatsuki, Seiji

PY - 2013/1

Y1 - 2013/1

N2 - Atrial fibrillation (AF) and coronary artery disease (CAD) can be comorbid with each other, because they can develop based on common risk factors such as aging, hypertension, diabetes mellitus and obesity. The management for stroke prevention in patients with AF and CAD needs some cautions. The vascular disease including CAD has been approved as one of the risk developing stroke in the CHA2DS2-VASc score for patients with AF. Patients with AF and CAD often should take antiplatelet and anticoagulant and sometimes take double antiplatelets and anticoagulant, which associates with increased bleeding risk. On terms of the management of AF, the medications of the rhythm control therapy for the AF would be limited if a patient has CAD. A K channel blocker would be selected for the 1st line therapy.

AB - Atrial fibrillation (AF) and coronary artery disease (CAD) can be comorbid with each other, because they can develop based on common risk factors such as aging, hypertension, diabetes mellitus and obesity. The management for stroke prevention in patients with AF and CAD needs some cautions. The vascular disease including CAD has been approved as one of the risk developing stroke in the CHA2DS2-VASc score for patients with AF. Patients with AF and CAD often should take antiplatelet and anticoagulant and sometimes take double antiplatelets and anticoagulant, which associates with increased bleeding risk. On terms of the management of AF, the medications of the rhythm control therapy for the AF would be limited if a patient has CAD. A K channel blocker would be selected for the 1st line therapy.

UR - http://www.scopus.com/inward/record.url?scp=84881325806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881325806&partnerID=8YFLogxK

M3 - Article

C2 - 23631186

AN - SCOPUS:84881325806

VL - 71

SP - 142

EP - 147

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 1

ER -